Evaluation of Depth of Invasion and Tumor Thickness as a Prognostic Factor for Early-Stage Oral Squamous Cell Carcinoma: A Retrospective Study

The aim of this study was to compare the effect of using depth of invasion (DOI) versus tumor thickness (TT) as a prognostic factor for early-stage oral squamous cell carcinoma (OSCC). A total of 57 patients with early-stage OSCC treated surgically from 2009 to 2014 at our institution were reviewed retrospectively. Histopathological measurement of DOI and TT was performed. The validation of DOI and TT as prognostic factors was conducted using a Kaplan–Meier survival analysis. TT had no association with disease-specific survival (DSS) or progression-free survival (PFS) in this cohort; however, increased DOI was significantly associated with decreased DSS but not correlated to decreased PFS. The T category of the 7th edition of AJCC was statistically associated with both DSS and PFS; however, the T category of the 8th edition of the AJCC was only associated with DSS. In this study group, TT could not be used as a prognostic factor, and DOI was not by itself sufficient to predict prognosis for early-stage OSCC. The T category in AJCC 8th Edition cannot be considered the sole prognostic factor for early OSCC, so additional prognostic factors may need to be considered.

Retinoblastoma Survival Following Primary Enucleation by AJCC Staging

Primary enucleation of the eye with retinoblastoma is a widely accessible, life-saving treatment for retinoblastoma. This study evaluated the survival of patients following primary enucleation based on AJCC 8th edition staging. Included were 700 consecutive patients (700 eyes) treated with primary enucleation at 29 Chinese treatment centers between 2006 and 2015. Excluded were patients with less than one year follow-up, bilateral retinoblastoma, clinical evidence of extraocular disease at diagnosis, or prior focal or systemic therapy. The 5-year overall survival was 95.5%, and 5-year disease-specific survival (DSS) was 95.7%. Survival was better when enucleation was <26 days from diagnosis than delayed >26 days (96.1% vs. 86.9%; p = 0.017). Patients with eyes presenting with raised intraocular pressure with neovascularization and/or buphthalmos (cT3c) had worse 5-year DSS (87.1%) than those without (cT2b, 99.1%; cT3b, 98.7%; cT3d, 97.2%) (p < 0.05). The 5-year DSS based on pathological staging was pT1 (99.5%), pT2a (95.5%), pT3a (100%), pT3b (93.0%), pT3c/d (92.3%), and pT4 (40.9%). Patients with pT3 pathology who received six cycles of adjuvant chemotherapy had better 5-year DSS (97.7%) than those with no chemotherapy (88.1%; p = 0.06) and those who underwent 1–3 cycles (86.9%, p = 0.02) or 4–5 cycles (89.3%, p = 0.06). Patients with pT4 pathology who received six cycles of chemotherapy had better 5-year DSS than those with 0–5 cycles (63.6% vs. 16.7%; p = 0.02). Prompt primary enucleation yielded high long-term survival for children with retinoblastoma. The AJCC 8th edition staging is predictive of survival.

Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer

The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive. Peritoneal recurrence is the common and severe relapse pattern. Nanoparticle albumin-bound paclitaxel (Nab-PTX) is safer and more effective than PTX in the peritoneal metastasis. Clinical trial has demonstrated the safety and efficacy of sintilimab in GC. A combination of Nab-PTX, S-1 and sintilimab could be a promising triplet regimen as adjuvant therapy for GC. The aim of this article is to describe the design of this prospective Dragon-VII trial, conducted to evaluate the safety and efficacy of the combination of Nab-PTX, S-1 and sintilimab. Trial registration: NCT04781413

Thymomas: Analysis of Histological Subtypes and Staging in Patients with Surgical Treatment in Two Reference Centers in Argentina

Background: Thymomas are a heterogeneous group of tumors which represent the most frequent tumor of the anterior mediastinum. Aims: To describe the clinical, histological, surgical and oncological characteristics of a cohort of patients with a diagnosis of thymoma surgically treated in two centers in Argentina and to evaluate the possibility of retrospectively implementing the 8th edition of TNM staging. Materials and Methods: 180 patients with thymoma surgically treated over a period of 41 years were studied. The following variables were analysed: age, sex, presence of myasthenia gravis at diagnosis, Masaoka staging (1994), TNM staging of thymus tumors, Histological classification (WHO 2015), neoadjuvant treatment with chemotherapy, post-operative radiation treatment and clinical evolution of myasthenia gravis defined according to the modified Osserman classification. Results: 96 men and 84 women were analysed. Median age 51 years (range 13-85). 85% of the patients analysed came from the public sphere. When analysing the institutional distribution by Masaoaka-Koga stage and TNM, a higher proportion of stages I was observed for both staging systems. Most myasthenic patients belonged to the WHO B2 histological classification (49%, p=0.04) and 15 patients received neoadjuvant treatment prior to surgery to improve the chances of resection, most of them classified as stages III of Masaoka (p=0.002) or IIIa of the TNM stage (p=0.001). 74 (46%) cases received post-operative RT when they presented Masaoka Koga stages II (p=0.000) and IIIa or more advanced TNM staging (p=0.000). 76% of the patients presented remission or stability of symptoms after surgical treatment and only 3/6 died due to myasthenic crisis in the immediate post-operative period. Conclusion: As reported in the literature, we have observed a higher frequency of B2 thymomas and their association with Myasthenia gravis. The histological criteria of the WHO 2015 classification, based on the ITMIG recommendations, favour precision in the definition of subtypes. The retrospective implementation of the 8th edition of TNM staging highlights the need to standardize protocols for pathological and surgical studies.

Projection of Impaired Life Expectancy for Individuals in the United Kingdom Using Estimated Excess Death Rates

We have recently constructed tables of the estimated life expectancies of impaired lives on the basis of mortality ratios and the cohort life expectancy tables given in the 8th edition of the Ogden Tables, which are derived from the ONS 2018-based population projections for the United Kingdom.1,2 The life expectancy of impaired lives may also be estimated using excess death rates. In this paper, we give tables of life expectancies for impaired lives using a range of excess death rates for males and females from age 0 to age 100. As both mortality ratios and excess death rates are widely used in medical and legal settings, it is hoped that these additional tables of life expectancies will be of practical value.